XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Oct. 31, 2017 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2017 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2018
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Revenues |  | $ 18,253,000 | $ 18,741,000 |  | $ 52,192,000 | $ 38,996,000 |
Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  | $ 150,000,000.0 |  |  |
Potential development and regulatory milestone payments under agreement | $ 420,000,000.0 |  |  |  |  |  |
Potential commercial milestone payments under agreement | 330,000,000.0 |  |  |  |  |  |
Development and regulatory milestones recognized |  |  |  |  | 30,000,000.0 |  | $ 15,000,000.0
Collaborative agreement transaction price | 154,000,000.0 |  |  |  |  |  |
Incyte Corporation | Incyte MGA012 Agreement - Clinical activities |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Variable consideration recognized | $ 4,000,000.0 |  |  |  |  |  |
Maximum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Potential proceeds from royalties (percent) | 24.00% |  |  |  |  |  |
Minimum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Potential proceeds from royalties (percent) | 15.00% |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Development and regulatory milestones recognized |  | 15,000,000.0 | 15,000,000.0 |  |  |  |
Revenues | $ 150,000,000.0 |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Revenues |  |  | 0 |  |  | 0 |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Revenues |  | $ 700,000 | $ 4,900,000 |  | $ 8,100,000 | $ 13,100,000 |

X
- References No definition available. + Details
Name: | mgnx_CollaborativeAgreementTransactionPrice
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development And Regulatory Milestone Payments Under Agreement, Recognized + References No definition available. + Details
Name: | mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_PotentialCommercialMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_ProceedsfromRoyaltiesPercent
Namespace Prefix: | mgnx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount + References No definition available. + Details
Name: | mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |